Overview
Bkemv is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (the destruction of red blood cells). Eligiblility for this…

Overview
Empaveli is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Empaveli is also known by its drug name, Pegcetacoplan.

…

Overview
Epysqli is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (breakdown of red blood cells). Before starting this…

Overview
Fabhalta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is also known by its drug name, iptacopan…

Overview
PiaSky is approved by the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and children 13 years and older who weigh at least 40 kilograms (around…

Overview
Soliris is approved by the U.S. Food and Drug Administration (FDA) to treat people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is prescribed for individuals with PNH to reduce hemolysis (destruction…

Overview

Ultomiris is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 1 month or older with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is also referred to by its drug…

Overview
Voydeya is approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy to either ravulizumab or eculizumab for the treatment of extravascular hemolysis (destruction of red blood cells outside of…